After reconsidering, Canada’s Drug Agency issued a final recommendation supporting public reimbursement of lecanemab, sold as LEQEMBI.
Getting a drug approved is the easy half of the job. Getting someone else to pay for it is the half that actually determines who takes it. Canada just cleared that second, harder hurdle for LEQEMBI.
On 31 August, Canada’s Drug Agency issued a final recommendation supporting public reimbursement of lecanemab for eligible patients with mild cognitive impairment or mild dementia caused by Alzheimer’s disease [1]. The recommendation came after a reconsideration, meaning the agency’s first answer wasn’t this one. Agencies don’t usually revisit a decision without new evidence, sustained pressure or both. Either way, the outcome now on the table is a formal opening for eligible Canadians to access the drug without shouldering the full cost themselves.
That opening isn’t the finish line, though. Next comes price negotiation through the pan-Canadian Pharmaceutical Alliance, the body that bargains on behalf of the country’s provinces and territories, followed by separate coverage decisions in each province. Canada runs healthcare provincially, so a national recommendation sets direction without guaranteeing the same rollout timeline everywhere.
Roughly 770,000 people in Canada were estimated to be living with dementia in 2025. The Alzheimer Society of Canada projects that figure will hit 1.7 million by 2050. Health systems don’t wait for numbers like that to arrive before reorganizing budgets around them, and how Canada handles reimbursement for one of the first antibody therapies on the market will likely shape how it treats the next wave.
Lecanemab, developed through a research partnership between Eisai and the Swedish biotech BioArctic, is a lab-made antibody that targets amyloid-beta, specifically a toxic, soluble form called protofibrils, before it fully hardens into the plaques that have dominated public conversation about Alzheimer’s for decades. Protofibrils are increasingly understood to do much of the early damage themselves, disrupting communication between brain cells before plaques even finish forming. Clear them out earlier, the theory goes, and you slow how fast memory and thinking decline.
The drug already has approval in 53 countries and regions, including the US, Japan, China and the UK, with six more under review. Dosing has become easier over time, too. A subcutaneous, at-home injection for ongoing maintenance won US approval in 2025; an easier subcutaneous starting dose followed in July 2026. Both changes are aimed at the same problem: a drug that once required recurring infusion visits is a much harder ask for a patient managing it over years rather than months.
Eisai leads lecanemab’s global development and regulatory strategy, with Biogen co-commercializing and co-promoting the drug. The two companies have worked together on Alzheimer’s treatments since 2014, an arrangement that traces back to a 2005 collaboration with BioArctic. Multi-company partnerships like this one have become close to standard in Alzheimer’s drug development, largely because the cost and risk of getting a single therapy to market now routinely exceeds what any one company wants to carry alone.
It’s worth reading this decision against the rest of the Alzheimer’s and neurodegeneration pipeline right now, from early-stage biotechs chasing entirely different mechanisms, like tau-targeting oral pills still in Phase 1 trials, to prevention studies such as AHEAD 3-45, which is testing lecanemab in people who are cognitively normal but already carry elevated amyloid. Reimbursement decisions like this one don’t just settle who can access one existing drug. They set a template (and a price benchmark) for how payers everywhere will likely evaluate the next several Alzheimer’s therapies as they reach market over the coming years.
That template matters more than any single efficacy number for longevity science broadly. Extending healthy lifespan only means something if the therapies capable of doing it, especially for a disease that erodes independence and identity years before it ends life, actually reach the people who need them. A positive reimbursement decision doesn’t guarantee that happens. A negative one guarantees it doesn’t, no matter how well a drug performs in trials.
